Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression (TTP) exceeding that of last prior therapy in many cases.
This label update provides physicians with important information on the clinical utility of rivaroxaban in patients with AF who require cardioversion and is based on the positive CHMP
The AbbVie Innovation Center plans to employ more than 18 students, from undergraduate to graduate level, on a part-time basis throughout the year. Eight students have started working
Based on the antioxidant supplement used in The National Eye Institute’s (NEI) AREDS 2 study, ProVision leverages today’s best research on nutritional support for macular health to create
Solasia is currently completing a Phase I study of darinaparsin in Japan and South Korea to treat patients with relapsed and refractory peripheral T-cell lymphoma (hereinafter "PTCL"). Solasia
The new partnership with Janssen brings to nine the number of pharmaceutical companies around CQDM’s table, increasing the financial leverage that partners generate together. Thanks to CQDM’s unique
This NIH/National Institute of Neurological Disorders and Stroke (NINDS) award will support NIH’s Drug Manufacturing and Formulation Program (DMFP), which is a component of the Blueprint Neurotherapeutics Network
Dipraglurant, a novel small molecule inhibitor of the metabotropic glutamate receptor 5, has shown promise in the treatment of levodopa-induced dyskinesia and dystonia in Parkinson’s disease. Dipraglurant has
OnCore would continue as a subsidiary of Tekmira, and the licensing agreement for NVP018 between NeuroVive and OnCore will remain in force following the merger as the combined
This relationship will allow Abattis Bioceuticals Corp the exclusive license for Cannabidiol rich hemp oil products delivered directly to licensed physicians and dispensaries. Empirical Labs is a high
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.